> the problem is that many poor nations lack the prerequisites of manufacturing high-quality vaccines At least wrt Moderna (and I think Biontech as well), isn

> the problem is that many poor nations lack the prerequisites of manufacturing high-quality vaccines At least wrt Moderna (and I think Biontech as well), isn’t the issue also that part of the production process are not patented, but trade-secrets and thus simply not available? I’ve read this multiple times, but so far I have to find a definitive answer (true or false) either way ;)